Prevention and treatment of late complications of Parkinson’s disease
- Autores: Zakharov V.V1
-
Afiliações:
- FSAEI HE I.M. Sechenov First Moscow State Medical University MHRF (Sechenov University)
- Edição: Nº 19 (2017)
- Páginas: 14-19
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/290027
- ID: 290027
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The late stages of Parkinson’s disease are characterized by a change in the response to dopaminergic therapy with the formation of motor fluctuations and dyskinesias, the development of pronounced autonomic and cognitive insufficiency. The risk of development of motor fluctuations and dyskinesias after the initiation of therapy with levodopa is 10% per year. Therefore, in the late stages of Parkinson’s disease, it is necessary to modify the antiparkinsonian therapy with the crossover to prolonged dosage forms, and specific treatment of existent autonomic and cognitive disorders. Long-term therapy with amantadine is beneficial, because it reduces the likelihood and delays the development of dementia, helps to reduce the severity of motor fluctuations, and has an antidyskinetic effect.
Texto integral
Sobre autores
V. Zakharov
FSAEI HE I.M. Sechenov First Moscow State Medical University MHRF (Sechenov University)
Email: zakharovenator@gmail.com
MD, Prof. at the Department of Nervous Diseases and Neurosurgery
Bibliografia
- Tysnes O.B., Storstein A. Epidemiology of Parkinson's disease. J. Neural. Transm. 2017;124(8):901-5.
- Голубев В.Л. Побочные эффекты длительной терапии паркинсонизма препаратами леводопы и их коррекция. РМЖ. 1997;4:41-4.
- Lee C.S. Levodopa-induced dyskinesia -Mechanisms and management. B.C. Med. J. 2001;43(4):206-9.
- Левин О.С. Развитие моторных флюктуаций у больных с различными стадиями болезни Паркинсона. Нервные болезни. 2005;1:10-6.
- Нодель М.Р., Яхно Н.Н. Двигательные флуктуации и дискинезии при болезни Паркинсона: новые возможности терапии. Неврологический журнал. 2007;2:26-34.
- Федорова Н.В., Грачев И.С. Леводопаиндуцированные дискинезии при болезни Паркинсона: эффективность амантадина сульфата. Неврологический журнал. 2009;1:43-8.
- Schrag A., Quinn N. Parkinson's disease: a comunity based study. Brain. 2000;123(11): 2297-305.
- Oliveri R.L., Annesi G., Zappia M., Civitelli D., Montesanti R., Branca D., Nicoletti G., Spadafora P., Pasqua A.A., Cittadella R., Andreoli V., Gambardella A., Aguglia U., Quattrone A. Dopamine D2 receptor gene polymorphism and the riak of levodopa-induced dyskinesias in PD. Neurology. 1999;53:1425-30.
- Olanow C.W., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology. 1998; 50(3):27-30.
- Иллариошкин С.Н. Современные подходы к лечению болезни Паркинсона. Атмосфера. Нервные болезни. 2004;4:14-6.
- Левин О.С., Артемьев Д.В., Бриль Е.В., Кулуа Т.К. Болезнь Паркинсона: современные подходы к диагностике и лечению. Практическая медицина. 2017;1:45-51.
- Schwab R.S., England A.C. Jr, Poskanzer D.C., Young R.R. Amantadine in treatment of Parkinson's disease. JAMA. 1969;208: 1168-70.
- Gianutsos G., Chutr S., Dunn J.P. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur. J. Pharmacol. 1985;110:357-61.
- Von Voigtlander P.F., Moore K.E. Dopamin release from the brain in vivo by amantadine. Science. 1973;174:408-10.
- Snow B.J., Macdonald L., Mcauley D., Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: double-blind, placebo-controlled study. Clin. Neuropharmacol. 2000;23(2):82-5.
- Thomas A., lacono D., Luciano A.L., Armellino K., Di lorio A., Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 2004;75:141-43.
- Pappa S., Tsouli S., Apostolou G., Mavreas V., Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized double blind placebo controlled study. Clin. Neuropharmacol. 2010;33(6):271-75.
- Crespo-Burillo J.A., Alarsio-Alejos R. Management of autonomic dysfunction in Parkinson's disease. Rev. Neurol. 2015;60(8):355-64.
- Dubow J.C. Autonomic dysfunction in Parkinson's disease. Dis. Mon. 2007;53(5):265-74.
- Ziemssen T., Fuchs G., Greulich W., Reichmann H., Herting B. Treatment of dysautonomia in extrapyramidal disorder. J. Neurol. 2011;258(Suppl. 2):339-45.
- Hubble J.P., Koller W.C. The parkinsonian personality. Adv. Neurol. 1995;65:43-8.
- Левин О.С. Психические расстройства при болезни Паркинсона и их коррекция. В кн.: Экстрапирамидные расстройства: Руководство по диагностике и лечению. Под ред. В.Н. Штока, И.А. Ивановой-Смоленской, О.С. Левина. М., 2002. С. 125-51.
- Aarsland D., Andersen K., Larsen J.P., Lolk A., Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson's disease: a 8-year prospective study. Arch. Neurol. 2003;60(3):387-92.
- Захаров В.В., Ярославцева Н.В., Яхно Н.Н. Когнитивные нарушения при болезни Паркинсона. Неврологический журнал. 2003;8(2):11-6.
- Захаров В.В. Когнитивные нарушения у пациентов с болезнью Паркинсона. Журнал неврол. и психиатр. 2005;1:13-9.
- Robbins T.W., James M., Owen A.M., Lange K.W., Lees A.J., Leigh P.N., Marsden C.D., Quinn N.P., Summers B.A. Cognitive deficit in progressive supranuclear palsy, Parkinson's disease and multisistem atrophy in tests sensitive to frontal lobe dysfunction. J. Neurol. Neurosurg. Psychiatr. 1994;57:79-88.
- Starkstein S.E., Bolduc P.L., Mayberg H.S., Preziosi T.J., Robinson R.G. Cognitive impairments and depression in Parkinson's disease: a follow-up study. J. Neurol. Neurosurg. Psychiatry. 1990;53:597-602.
- Степкина Д.А., Захаров В.В. Влияние мемантина на когнитивные функции у пациентов с болезнью Паркинсона. Неврологический журнал. 2008;13(2):43-7.
- Emre M., Aarsland D., Albanese A., Byrne E.J., Deuschl G., De Deyn P.P., Durif F., Kulisevsky J., van Laar T., Lees A., Poewe W., Robillard A., Rosa M.M., Wolters E., Quarg P., Tekin S., Lane R. Rivastigmine for dementia associated with Parkinson's disease. New Engl. J. Med. 2004;351(24):2509-18.
- Incelberg R., Bonucceli U., Schechtman E., Miniowich A., Strugatsky R., Ceravolo R., Logi C., Rossi C., Klein C., Rabey J.M. Association between amantadine and the onset of dementia in Parkinson's disease. Mov. Dis. 2006;21(9):1375-79.
Arquivos suplementares
